個別化がんワクチンの市場規模、シェア、動向分析レポート：タイプ別、技術別、流通チャネル別、地域別、セグメント予測、2025年～2030年

個別化がんワクチン市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の個別化がんワクチン市場規模は、2025～2030年にかけて44.86％のCAGRを記録し、2030年には14億5,000万米ドルに達すると予測されています。

免疫療法、ゲノミクス、mRNA技術の融合が市場成長の原動力となっています。従来型ワクチンとは異なり、これらの個別化療法は、特定の遺伝子変異から生じる新抗原を標的とし、各患者固有の腫瘍プロファイルに合わせて調整されます。この精度の高さにより、特に治療が困難ながんを対象に、腫瘍学に新たな治療の地平が開けています。市場の成長は、バイオテクノロジーへの投資の増加、世界のがん罹患率の増加、次世代シーケンサーの進歩によって推進されています。モデナの欧州医薬品庁PRIME指定やMerckのmRNA-4157/V940の2023年4月指定など、臨床検査から薬事指定への急速な進展はこの勢いを象徴しています。これらのワクチンはもはや投機的な治療ではなく、将来の腫瘍学の展望に不可欠なものとなりつつあります。

市場成長の最も重要な促進要因のひとつは、mRNAベースのワクチンプラットフォームの革新です。COVID-19 mRNAワクチンの成功は、この治療法に対する官民セクタの信頼を加速させ、資金調達の増加と規制当局への迅速な対応につながりました。Merck社と共同開発したModernaの治験用ワクチン、mRNA-4157/V940は、この進歩の一例です。2023年4月にEMAからPRIME指定を受けたこのワクチンは、第2b相臨床検査（KEYNOTE-942）で有望な結果を示し、特にMerck社の免疫療法薬KEYTRUDAと組み合わせた場合に顕著でした。同様に、mRNA技術のパイオニアであるバイオエヌテックは、2024年4月に開催されたAACR年次総会で、mRNAベースのがんワクチンと抗体薬剤複合体を中心に、がん領域のパイプラインを展示しました。これらの技術革新により、研究者は腫瘍の塩基配列に基づいてワクチン候補を迅速に生成し、ほぼリアルタイムで治療を個別化し、免疫反応を微調整して有効性を高めることができるようになり、がん治療の新時代への道が開かれつつあります。

HPV感染、関連する健康リスク、ワクチン接種の利点に関する世界の意識の高まりは、市場成長を促進する主要因です。公衆衛生キャンペーン、ソーシャルメディアアウトリーチ、学校ベースの教育イニシアティブは、認識を変え、ワクチンの受け入れを促す上で極めて重要な役割を果たしています。オーストラリアや英国など、ヘルスケア・コミュニケーション戦略がしっかりしている国では、HPVワクチンの接種率が際立って高く、これは一貫したエビデンスによる啓発活動の効果を反映しています。性別にとらわれないワクチン接種のメッセージングは、特に男性における中咽頭がんや肛門がんの罹患率の増加を受けて、男性集団の受け入れも改善しています。セクシャルヘルスに対する偏見が薄れ、ワクチン接種の長期的ながん予防効果がより多くの人々に認識されるにつれ、より幅広い層の人々がワクチン接種を受けるようになっています。このような認識向上への取り組みは、需要を増加させるだけでなく、ワクチン接種の早期化、コンプライアンス率の向上、より安定した市場成長にもつながっています。

個別化がんワクチン産業を加速させる上で、規制上のインセンティブが重要な役割を果たしています。EMAのPRIMEスキームやFDAのブレークスルーセラピー指定のようなプログラムは、重篤な疾患に対する有望な治療法の開発を促進するように設計されています。ModernaとMerckのmRNA-4157/V940ワクチンがPRIMEに指定されたことは、がん領域におけるイノベーションを促進するという規制当局のコミットメントの証です。この指定は、高リスクのステージIII/IVのメラノーマ患者がKEYTRUDAと並行してワクチンを投与された場合、術後の転帰が改善したことを示唆する肯定的な中間データに基づいています。同様に、バイオエヌテックがAACR2024のような主要な科学フォーラムに参加し、重要な臨床的最新情報を明らかにしたことは、規制当局と科学的検証の高まりを強調しています。こうした市場の開拓は、投資家の信頼を高め、新規治療の市場投入までの時間を短縮し、特にアジュバント療法において治療選択肢が限られているがん患者に希望を与えることにつながります。

個別化がんワクチン市場レポートハイライト

• タイプ別では、樹状細胞セグメントが2024年に100%の最大市場シェアを占め、標的免疫療法と個別化免疫療法の需要増に牽引されました。
• 細胞ベース技術セグメントは、標的化・適応化抗腫瘍反応のために体内の免疫系を利用する能力に支えられ、2024年の収益シェア100%で市場をリードしました。このセグメントには、患者由来の細胞、特に樹状細胞、腫瘍浸潤リンパ球（TIL）、または人工T細胞を利用して腫瘍特異的抗原を提示し、がん細胞に対する個別化免疫攻撃を刺激する治療法が含まれます。
• 病院セグメントは、2024年の収益シェア58.87％で市場を独占し、いくつかの重要な要因によって、予測期間中に最も速いCAGRで成長すると予想されています。病院は、がんの診断、治療、フォローアップケアの主要センターとしての役割を果たします。
• 北米は、免疫療法の進展と強力なヘルスケアインフラが牽引し、2024年には34.07%のシェアを獲得して世界市場を席巻しました。この成長の原動力となっているのは、がん罹患率の増加であり、米国だけでも2022年には190万人のがん患者が新たに発生すると推定されています。
• 世界の個別化ワクチン産業は、Dendreon Pharmaceuticals, LLC、Gritstone Bio、CureVac、NeoCura & Innovent、Stemirna Therapeutics、Dendreon Pharmaceuticals, LLC、Elicio Therapeutics、Evaxion BIoTech、Imugene、Nouscomなどの主要企業が牽引しており、これらの企業は新製品の上市、戦略的パートナーシップの締結、新たな地域への進出などの戦略を通じて、世界的プレゼンスを強化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 個別化がんワクチン市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場動向と展望
• 市場力学
  • ゲノムと免疫療法技術の進歩
  • がん罹患率の上昇と標的治療の需要
  • がん免疫療法における協力と投資の増加
• 市場抑制要因分析
  • 開発・製造コストが高め
  • 規制と物流上の課題
  • ポーターのファイブフォース分析
  • PESTEL分析

第4章 個別化がんワクチン市場：タイプ別、推定・動向分析

• 個別化がんワクチン市場：タイプ変動分析
• タイプ別
• 樹状細胞
• RNAベース（mRNA）
• ネオアンチゲンベース
• 腫瘍関連抗原（TAA）ワクチン
• 個別化がんワクチン市場：技術変動分析
• 技術別
• 細胞ベース
• mRNA PCV
• その他

第5章 個別化がんワクチン市場：流通チャネル別、推定・動向分析

• 個別化がんワクチン市場：流通変動分析
• 流通チャネル別
• 病院
• クリニック
• 研究・学術機関

第6章 個別化がんワクチン市場：地域別、推定・動向分析

• 個別化がんワクチン市場シェア（地域別）、2024年と2030年
• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 北米の個別化がんワクチン市場、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州の個別化がんワクチン市場、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の個別化がんワクチン市場、2018～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ラテンアメリカの個別化がんワクチン市場、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの個別化がんワクチン市場、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 戦略マッピング
• 企業市場シェア分析、2024年
• 企業プロファイル
  • Dendreon Pharmaceuticals, LLC
  • Gritstone Bio
  • CureVac
  • NeoCura & Innovent
  • Stemirna Therapeutics
  • Elicio Therapeutics
  • Evaxion BIoTech
  • Imugene
  • Nouscom

List of Tables

• Table 1 List of abbreviations
• Table 2 Global Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 3 Global Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 4 Global Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 5 Global Personalized Cancer Vaccine Market, by Region, 2018 - 2030 (USD Million)
• Table 6 North America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 8 North America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 9 North America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 11 U.S. Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 12 U.S. Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 14 Canada Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 15 Canada Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Mexico Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 17 Mexico Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 18 Mexico Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 20 Europe Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 21 Europe America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 22 Europe America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 UK Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 24 UK Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 25 UK Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 27 Germany Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 28 Germany Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 30 France Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 31 France Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 33 Italy Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 34 Italy Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 36 Spain Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 37 Spain Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 39 Denmark Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 40 Denmark Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 42 Sweden Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 43 Sweden Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 45 Norway Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 46 Norway Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 52 Japan Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 53 Japan Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 55 China Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 56 China Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 58 India Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 59 India Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Australia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 61 Australia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 62 Australia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Thailand Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 64 Thailand Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 65 Thailand Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 South Korea Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 67 South Korea Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 68 South Korea Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 71 Latin America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 72 Latin America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 74 Brazil Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 75 Brazil Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Argentina Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 77 Argentina Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 78 Argentina Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Personalized Cancer Vaccine Market, by type, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 South Africa Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 85 South Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 88 audi Arabia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 UAE Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 90 UAE Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 91 UAE Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Kuwait Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
• Table 94 Kuwait Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Personalized Cancer Vaccine Market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Personalized cancer vaccine market: Type movement analysis
• Fig. 15 Personalized cancer vaccine market: Type outlook and key takeaways
• Fig. 16 Dendritic Cell market estimates and forecast, 2018 - 2030
• Fig. 17 RNA-Based (mRNA) market estimates and forecast, 2018 - 2030
• Fig. 18 Neoantigen-based market estimates and forecast, 2018 - 2030
• Fig. 19 Tumor-Associated Antigen (TAA) vaccines market estimates and forecast, 2018 - 2030
• Fig. 20 Personalized cancer vaccine market: Technology movement analysis
• Fig. 21 Personalized cancer vaccine market: Technology outlook and key takeaways
• Fig. 22 Cell-based market estimates and forecast, 2018 - 2030
• Fig. 23 mRNA PCV market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 Personalized cancer vaccine market: Distribution channel movement analysis
• Fig. 26 Personalized cancer vaccine market: Distribution channel outlook and key takeaways
• Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 28 Clinics market estimates and forecast, 2018 - 2030
• Fig. 29 Research & academic institutes market estimates and forecast, 2018 - 2030
• Fig. 30 Government suppliers market estimates and forecast, 2018 - 2030
• Fig. 31 Regional outlook, 2024 & 2030
• Fig. 32 Global Personalized Cancer Vaccine Market: Region movement analysis
• Fig. 33 North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 35 Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 36 Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 37 Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 38 Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 39 UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 40 France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 41 Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 42 Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 43 Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 45 Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 46 Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 47 Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 48 China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 49 India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 50 Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 51 South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 52 Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 53 Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 54 Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 55 Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 56 Middle East and Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 57 South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 59 UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• Fig. 60 Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Personalized Cancer Vaccine Market Growth & Trends:

The global personalized cancer vaccine market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 44.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The convergence of immunotherapy, genomics, and mRNA technologies drives the market growth. Unlike traditional vaccines, these personalized therapies are tailored to each patient's unique tumor profile, targeting neoantigens that arise from specific genetic mutations. This precision has opened new therapeutic horizons in oncology, especially for hard-to-treat cancers. The market growth is propelled by increasing investments in biotechnology, growing incidence of cancer worldwide, and advancements in next-generation sequencing. The rapid progression from clinical trials to regulatory designations, such as the European Medicines Agency's PRIME designation for Moderna and Merck's mRNA-4157/V940 in April 2023, is emblematic of this momentum. These vaccines are no longer speculative treatments; they are becoming integral to the future oncology landscape.

One of the most pivotal drivers of market growth is innovation in mRNA-based vaccine platforms. The success of COVID-19 mRNA vaccines accelerated public and private sector confidence in the modality, leading to increased funding and faster regulatory pathways. Moderna's investigational vaccine, mRNA-4157/V940, developed in partnership with Merck, exemplifies this progress. Granted PRIME designation by the EMA in April 2023, the vaccine showed promising results in Phase 2b trials (KEYNOTE-942), especially when paired with Merck's immunotherapy drug KEYTRUDA. Similarly, BioNTech, a pioneer in mRNA technology, showcased its oncology pipeline at the AACR Annual Meeting in April 2024, highlighting its mRNA-based cancer vaccines and antibody-drug conjugates. These innovations are allowing researchers to rapidly generate vaccine candidates based on tumor sequencing, personalize therapies in near real-time, and fine-tune immune responses to enhance efficacy, paving the way for a new era in cancer treatment.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

Regulatory incentives are playing a crucial role in accelerating the personalized cancer vaccine industry. Programs like the EMA's PRIME scheme or the FDA's Breakthrough Therapy designation are designed to expedite the development of promising therapies for serious conditions. Moderna and Merck's mRNA-4157/V940 vaccine receiving PRIME status is a testament to the regulators' commitment to fostering innovation in oncology. This designation was based on positive interim data suggesting that patients with high-risk stage III/IV melanoma had improved outcomes post-surgery when treated with the vaccine alongside KEYTRUDA. Similarly, BioNTech's participation in major scientific forums like AACR 2024, where it revealed significant clinical updates, underscores growing regulatory and scientific validation. These developments help boost investor confidence, shorten time-to-market for novel therapies, and offer hope for cancer patients who have limited treatment options, especially in the adjuvant setting.

Personalized Cancer Vaccine Market Report Highlights:

• Based on type, the dendritic cell segment accounted for the largest market share of 100% in 2024, driven by increasing demand for targeted and individualized immunotherapies.
• The cell-based technology segment led the market with a 100% revenue share in 2024, underpinned by its ability to harness the body's own immune system for targeted and adaptive anti-tumor responses. This segment includes therapies that utilize patient-derived cells, particularly dendritic cells, tumor-infiltrating lymphocytes (TILs), or engineered T-cells, to present tumor-specific antigens and stimulate a personalized immune attack against cancer cells.
• The hospitals segment dominated the market with a revenue share of 58.87% in 2024 and is expected to grow at the fastest CAGR over the forecast period, driven by several key factors. Hospitals serve as primary centers for cancer diagnosis, treatment, and follow-up care
• North America dominated the global market, with a share of 34.07% in 2024, driven by advancements in immunotherapy and a strong healthcare infrastructure. This growth is fueled by the increasing prevalence of cancer, with the U.S. alone reporting an estimated 1.9 million new cancer cases in 2022.
• The global personalized vaccine industry is led by several major companies, including Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, all of which are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Cancer Vaccine Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Advances in genomic and immunotherapy technologies
  • 3.4.2. Rising cancer prevalence and demand for targeted treatments
  • 3.4.3. Collaborations and increased investment in cancer immunotherapy
• 3.5. Market Restraint Analysis
  • 3.5.1. High development and manufacturing costs
  • 3.5.2. Regulatory and logistical challenges
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Personalized Cancer Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Personalized Cancer Vaccine Market: Type Movement Analysis
• 4.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Type
• 4.3. Dendritic Cell
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. RNA-Based (mRNA)
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neoantigen-Based
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Tumor-Associated Antigen (TAA) Vaccines
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Personalized Cancer Vaccine Market: Technology Movement Analysis
• 4.8. Personalized Cancer Vaccine Market Estimates and Forecast, by Technology
• 4.9. Cell-based
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. mRNA PCV
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Personalized Cancer Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Personalized Cancer Vaccine Market: Distribution Movement Analysis
• 5.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Distribution Channel
• 5.3. Hospitals
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Research & Academic Institutes
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Personalized Cancer Vaccine Market: Regional Estimates & Trend Analysis

• 6.1. Personalized Cancer Vaccine Market Share By Region, 2024 & 2030
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Regional Market Dashboard
• 6.4. Global Regional Market Snapshot
• 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.6. North America
  • 6.6.1. North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.2. U.S.
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Canada
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.4. Mexico
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.7. Europe
  • 6.7.1. Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.2. UK
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.3. Germany
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.4. France
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.5. Italy
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.6. Spain
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.7. Denmark
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.8. Sweden
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.9. Norway
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.8. Asia Pacific
  • 6.8.1. Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.2. Japan
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.3. China
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.4. India
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.5. Australia
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.6. Thailand
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Competitive Scenario
    • 6.8.6.3. Regulatory Framework
    • 6.8.6.4. Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.7. South Korea
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Competitive Scenario
    • 6.8.7.3. Regulatory Framework
    • 6.8.7.4. South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.9. Latin America
  • 6.9.1. Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.3. Argentina
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.10. MEA
  • 6.10.1. MEA Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.2. South Africa
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Competitive Scenario
    • 6.10.2.3. Regulatory Framework
    • 6.10.2.4. South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.3. Saudi Arabia
    • 6.10.3.1. Key Country Dynamics
    • 6.10.3.2. Competitive Scenario
    • 6.10.3.3. Regulatory Framework
    • 6.10.3.4. Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.4. UAE
    • 6.10.4.1. Key Country Dynamics
    • 6.10.4.2. Competitive Scenario
    • 6.10.4.3. Regulatory Framework
    • 6.10.4.4. UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.5. Kuwait
    • 6.10.5.1. Key Country Dynamics
    • 6.10.5.2. Competitive Scenario
    • 6.10.5.3. Regulatory Framework
    • 6.10.5.4. Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Strategy Mapping
• 7.4. Company Market Share Analysis, 2024
• 7.5. Company Profiles
  • 7.5.1. Dendreon Pharmaceuticals, LLC
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Gritstone Bio
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. CureVac
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. NeoCura & Innovent
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Stemirna Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Elicio Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Evaxion Biotech
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Imugene
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Nouscom
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives